Abstract: Mast cells (MCs) are common components of inflammatory infiltrates and a source of proangiogenic factors. Inflammation is often accompanied by vascular changes. However, little is known about modulation of MC-derived proangiogenic factors during inflammation. In this study, we evaluated the effects of the proinflammatory mediator prostaglandin E 2 (PGE 2 ) on MC expression and release of proangiogenic factors. We report that PGE 2 dose-dependently induces primary MCs to release the proangiogenic chemokine monocyte chemoattractant protein-1 (MCP-1). This release of MCP-1 is complete by 2 h after PGE 2 exposure, reaches levels of MCP-1 at least 15-fold higher than background, and is not accompanied by degranulation or increased MCP-1 gene expression. By immunoelectron microscopy, MCP-1 is detected within MCs at a cytoplasmic location distinct from the secretory granules. Dexamethasone and cyclosporine A inhibit PGE 2 -induced MCP-1 secretion by ϳ60%. Agonists of PGE 2 receptor subtypes revealed that the EP 1 and EP 3 receptors can independently mediate MCP-1 release from MCs. These observations identify PGE 2 -induced MCP-1 release from MCs as a pathway underlying inflammation-associated angiogenesis and extend current understanding of the activities of PGE 2 . J. Leukoc. Biol. 79: 000 -000; 2006.
INTRODUCTION
It is well established that mast cells (MCs) located in the mucosa of the respiratory and gastrointestinal system or in the skin serve as the principal effector cells of type I hypersensitivity reactions that occur when sensitized individuals come in contact with allergens [1, 2] . Through exocytosis, MCs rapidly release a broad array of mediators, including histamine [3] , numerous proteases, and tumor necrosis factor ␣ (TNF-␣), which serve to mediate acute allergic reactions [4, 5] . MCs are also found in the connective tissue of many organs and localize around blood and lymphatic microvessels [6] . The broad tissue distribution of MCs in proximity to capillary vessels and their prominence in inflammatory infiltrates has suggested a wider range of MC activities than previously thought. Recently, genetic and functional experiments have provided strong evidence for a critical role of MCs in promoting tumor angiogenesis and tumor growth [7, 8] .
Unlike other cells within the inflammatory infiltrate, MCs are a rich source of factors that regulate angiogenesis, including heparin [9] , histamine [3] , vascular endothelial growth factor (VEGF)-A [10] , basic fibroblast growth factor (bFGF) [11] , angiopoietin (Ang)-1 [8] , Ang-2 [12] , interleukin (IL)-8 [13] , matrix metalloproteinases [14] , and monocyte chemoattractant protein (MCP)-1 [15] [16] [17] .
MCP-1 (CC chemokine ligand 2), a CC chemokine that serves as a major monocyte chemoattractant [18 -20] , can exert direct, proangiogenic functions by locally recruiting endothelial cells that express the MCP-1 receptor CC chemokine receptor 2 (CCR2) [21] . It can also promote angiogenesis indirectly, through chemotaxis of monocytes and macrophages, which are themselves proangiogenic [22] [23] [24] .
Prostaglandin E 2 (PGE 2 ), an arachidonic acid (AA) metabolite generated by the cyclooxygenase enzymes COX-1 and COX-2 in macrophages, fibroblasts, and other cells, is recognized as a potent, proinflammatory mediator, which exerts its biological activities by interaction with one or a combination of subtype receptors designated EP 1 , EP 2 , EP 3 , and EP 4 , variously induced by proinflammatory signals [25] . In some inflammatory conditions, a direct relationship is detected between inflammatory disease activity and levels of PGE 2 in tissues. COX-2 inhibitors, which can reduce PGE 2 production, are effective at reducing inflammation and inflammatory disease progression [26] . In a murine model of pristane-induced plasmacytomagenesis, indomethacine, a COX-2 inhibitor, which diminishes PGE 2 production, suppresses cancer development at the site of chronic inflammation [27] [28] [29] [30] .
MCs often participate in inflammatory processes associated with PGE 2 release and are detected in close proximity to PGE 2 -producing fibroblasts [31] and macrophages [32] . PGE 2 has been reported to favor MC development from murine spleen cell precursors [33] and from human umbilical cord blood mononuclear cells [34] and to promote or potentiate IL-6 production in murine bone marrow-derived MCs (BMMCs), acting through EP 1 and/or EP 3 receptors [35] . However, little is known about the effects of PGE 2 on MC release of proangiogenic factors. Recently, PGE 2 was reported to promote VEGF-A production in human cord blood mononuclear cellderived MCs via activation of the EP 2 receptor [36] . In this study, we have used well-characterized populations of primary murine MCs derived from the bone marrow (BMMC) and spleen {spleen-derived MC (SPMC) [15, 37] } to evaluate the effect of PGE 2 on MC expression and release of proangiogenic factors.
MATERIALS AND METHODS

Reagents and cells
PGE 2 and the PGE 2 analogs: butaprost, misoprostol, PGE 1 alcohol, 17-phenyl trinor--PGE 2 , and sulprostone were from Cayman Chemical (Ann Arbor, MI). Phorbol 12-myristate 13 acetate (PMA), calcium ionophore A23187, and dexamethasone (DM) were obtained from Sigma-Aldrich (St. Louis, MO). Cyclosporine A (CsA) was purchased from Novartis Pharmaceuticals (Basel, Switzerland). RPMI 1640 and fetal bovine serum (FBS) were purchased from Biofluids (Rockville, MD). BMMCs and SPMCs, obtained from C57BL/6 mice [National Cancer Institute (NCI), Frederick, MD], prepared as we described previously [8] , were cultured with RPMI-1640 medium containing 10% FBS, 50 M 2-mercaptoethanol, and 10 ng/mL IL-3 (Peprotech Corp, Seattle, WA) as described previously [8, 38, 39] . After 4 -5 weeks of culture, more than 98% of cells were identified as MC by toluidine blue staining or flow cytometry for surface c-kit and Fc receptor for immunoglobulin E (IgE; FcεR)I [8, 40] . WEHI-3 cells (a gift of Dr. M. Narazaki, Osaka University, Japan) were cultured in RPMI-1640 medium containing 10% FBS.
RNA preparation and reverse transcriptasepolymerase chain reaction (RT-PCR) analysis
Total RNA was extracted from BMMCs using TRIzol reagent (Molecular Research Center, Cincinnati, OH). cDNA was synthesized from 5 g total RNA using the SuperScript preamplification system (Gibco-BRL, Grand Island, NY), followed by DNase I treatment (Invitrogen, Carlsbad, CA). Semiquantitative RT-PCR was carried out to evaluate PGE 2 -induced modulation of MCP-1 mRNA. The amount of cDNA used for each amplification reaction was based on the results of PCR for glyceraldehyde 3-phosphate dehdyrogenase (GAPDH), showing equivalent amounts of product amplified from all samples. The number of amplification cycles was determined experimentally for each primer pair to fit the linear part of the sigmoid curve, reflecting the relationship between the number of amplification cycles and the amount of PCR product. Amplification was performed in a 50-L reaction mixture using 5 L (1:5 dilution) cDNA, platinum pfx Taq DNA polymerase (Invitrogen), and 1 L deoxy-unspecified nucleoside 5Ј-triphosphate (dNTP) mixture (10 mM; Gibco-BRL), and specific MCP-1 primers recognize mouse cDNA at appropriate annealing temperatures. MCP-1 and GAPDH were amplified for 26 and 29 cycles, respectively. PCR products were separated on 2% agarose gel (NuSieve agarose, FMC, Rockland, ME). Primer sequences for MCP-1, VEGF-A, VEGF-B, VEGF-C, Ang-1, and GAPDH were described elsewhere [41, 42] . PCR primers for amplification of CCR2 and information on patterns of CCR2 tissue expression were from the Jackson Laboratory (Bar Harbor, ME; MGI: 1205315, http://www.informatics.jax.org/). RNA from kidneys of C57BL/6 mice was used as a positive control. PCR amplification of CCR2 used 33 cycles. We adopted real-time quantitative RT-PCR (qRT-PCR) to evaluate the effect of PGE 2 on the mRNA expression of VEGF-A, VEGF-B, VEGF-C, and Ang-1. qRT-PCR was performed using the Roche LightCycler system (Roche Molecular Biochemicals, Roche Diagnostics Co., Indianapolis, IN) with a SYBR-Green I dye (Molecular Probes, Junction City, OR). Amplification was performed in a 20-L reaction mixture using 5 L cDNA (1:5 diluted), 0.4 L platinum Pfx Taq DNA polymerase (Gibco-BRL), 0.4 L dNTP mixture (10 mM, Gibco-BRL), 0. 8 l sense and antisense primer solution (50 M), and SYBR-Green I dye at a 1:10,000 dilution. The sequences of primer pairs for VEGF-A, VEGF-B, VEGF-C, and Ang-1 were described previously [43] [44] [45] [46] .
The optimal cycle program was determined for each gene in preliminary PCR runs to obtain a specific PCR product verified by melting curve analysis followed by gel electrophoresis. The absence of contaminating genomic DNA was ensured by RNA-PCR. The cDNA quantities were calculated by using the LightCycler analysis software, as described previously [47] . VEGF-A, VEGF-B, VEGF-C, and Ang-1 were normalized to GAPDH [42] .
MC activation in vitro and detection of MC products
To evaluateVEGF-A production, MCs (10 6 cells/mL) were incubated in culture medium (RPMI 1640, Biofluids) containing 1% fetal calf serum (FCS; Biofluids) for 3 h and then stimulated by PGE 2 (1000 nM) in complete medium. Ethanol (0.1%), used as a solvent of PGE 2 , was used as a relevant control for PGE 2 . After 12 h incubation, cell pellets were collected, and RNA was extracted for qRT-PCR. MC culture supernatants were obtained after cell culture for a period of 48, 72, 96 , and 120 h and were used for VEGF-A detection by a specific enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN). The lower limit of VEGF-A detection was measured at ϳ3 pg/mL. For time-course analysis of MCP-1 production and histamine release, MCs were washed twice with phosphate-buffered saline (PBS) and then incubated at 10 6 cells/mL for 0.5, 1, 2, 4, 6, or 24 h at 37°C in complete culture medium alone or with the addition of PGE 2 (1000 nM). Ethanol (0.1%) was used as a relevant control for PGE 2 . To identify PGE 2 receptor subtype(s) responsible for PGE 2 -induced MCP-1 secretion, BMMCs were incubated for 2 h with the following agents: PGE 2 (1000 nM), butaprost (1000 nM), misoprostol (1000 nM), PGE 1 alcohol (1000 nM), 17-phenyl--trinor-PGE 2 (1000 nM), and sulprostone (1000 nM). Ethanol (0.1%) was used as a relevant control for these reagents. For quantification of intracellular MCP-1 under basal conditions, BMMCs were solubilized in lysis buffer (1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate in PBS) containing protease inhibitor cocktail (Boehringer Mannheim, Germany) plus sodium fluoride (20 mM), and cell debris was removed by centrifugation. MCP-1 content in the culture supernatant or cell lysates was measured by a specific ELISA (R&D Systems). The lower limit of detection for MCP-1 was measured at ϳ2 pg/mL. At 0, 0.5, 1, 2, 3, 6, and 9 h time-points after incubation with PGE 2 (1000 nM), cell pellets were collected as well, and RNA was extracted for semiquantitative RT-PCR analysis. To evaluate VEGF-A production, MCs (10 6 cells/mL) were incubated in culture medium (RPMI 1640 containing 1% FCS) for 3 h and then stimulated by PGE 2 (1000 nM) in complete medium. Ethanol (0.1%) was used as a relevant control for PGE 2 . After 12 h incubation, cell pellets were collected, and RNA was extracted for qRT-PCR. MC culture supernatants were obtained after cell culture for a period of 48, 72, 96 , and 120 h and were used for VEGF-A detection by a specific ELISA (R&D Systems). The lower limit of VEGF-A detection was measured at ϳ3 pg/mL.
Histamine release measurement
To evaluate MC degranulation, we measured histamine release after PGE 2 stimulation, as described previously [48] . Briefly, MCs (10 6 cells/0.1 mL) were incubated in complete culture medium alone or with the addition of PMA (100 nM), calcium ionophore (1000 nM), and PGE 2 at various concentrations (1-5000 nM) for 60 min at 37°C. Ethanol (0.1%) was used as a relevant control for these reagents. Residual histamine in the cell pellet was released by boiling the cells for 20 min, followed by spinning to remove cell debris. The concentration of histamine in the culture supernatant and pellet samples was measured by a specific ELISA, following the manufacturer's instruction (ImmunoBiological Laboratories, Inc., Hamburg, Germany). The lowest limit of detection was determined at ϳ2.4 ng/mL. Concentrations of MCP-1 in culture supernatants were measured by a specific ELISA described above. The net percent histamine release was calculated as follows: histamine in supernatant/ (histamine in supernatantϩhistamine in pellet) ϫ 100 (%).
Fluorescein-activated cell sorter (FACS) analysis
Cell-surface CCR2 was detected by flow cytometry as described previously [49] . WEHI-3 cells, known to express low-level surface CCR2 [50] , were used as a positive control. Briefly, BMMCs, SPMCs, and WEHI-3 cells were incubated with 5 g/ml monoclonal antibody (mAb) MC-21 (a kind gift of Dr. M. Mack, Klinikum University, Regensburg, Germany) or with an isotype control antibody (rat IgG2b, BD PharMingen, San Diego, CA) for 60 min on ice. After washings, the cells were incubated for 45 min on ice with an Alexa 488-labeled anti-rat polyclonal antibody (Molecular Probes; Invitrogen). After washing, CCR2 expression was assessed from 1.0 ϫ 10 4 viable cells using a FACSCalibur cytofluorometer (Becton Dickinson, San Jose, CA) and analyzed using CELLQuest software (Becton Dickinson). Background fluorescence was assessed through staining with the isotype-matched antibody.
Ultrastructural localization of MCP-1
BMMCs maintained in culture as described above were fixed with 2.0% formaldehyde solution, followed by embedding in LR white plastic resin (EMBS Inc., Frederick, MD). Microthin sections (60 -80 nm) were cut, mounted onto 200 mesh nickel grids, and processed for immunocytochemistry. Grids were incubated with 20 g/ml hamster anti-mouse MCP-1 mAb: 2H5 (BD Pharminegen) or an isotype control mAb (BD PharMingen) for 4 h, followed by protein G conjugated to 10 nm gold particles (1/30, Polysciences, Warrington, PA). After 3 h incubation, sections were stained with uranyl acetate and Reynold's lead. Sections were examined (EMBS Inc.) using a JEOL 1200 EX transmission electron microscope (JEOL Inc., Peabody, MA).
Studies of the effects of CsA and DM on MCP-1 secretion
We evaluated the effects of CsA, a cyclic peptide produced by the fungus Tolypocladium inflatum and the glucocorticoid DM on the release of MCP-1 from MCs under conditions previously reported to inhibit MC degranulation [51, 52] . MCs were pretreated with CsA at 1 g/mL in complete culture medium for 1 h before addition of PGE 2 (1000 nM). In some experiments, MCs were washed three times with PBS to remove CsA prior to addition of PGE 2 , as described previously for cytotoxic T lymphocytes [53] . After 1 h incubation with PGE 2 , cell-free supernatants were tested for MCP-1 content. For DM treatment, MCs were preincubated with DM at 500 nM for 18 h and then incubated with PGE 2 , with or without washing, as described for CsA. Ethanol (0.1%), the solvent for CsA and DM, was used for a relevant control. All experiments were performed in triplicate. The percent MCP-1 release was calculated as follows: (MCP-1 release in CsA or DM group/MCP-1 release in control group) ϫ 100 (%).
Measurement of MC proliferation
The effects of PGE 2 on MC proliferation were assessed as described previously [54] . Cells were washed twice with PBS, suspended in culture medium (RPMI containing 10% FBS and 10 ng/mL IL-3), plated (20, 
Statistical analysis
Statistical significance of group differences was evaluated by Student's t-test using Excel software.
RESULTS
MCs release MCP-1 after PGE 2 stimulation
We tested the effect of PGE 2 on MC release of MCP-1 measured by a specific ELISA. Using cultures of previously characterized, primary murine MC derived from the bone marrow (BMMC) [8] , which contains ϳ800 pg/10 6 cells of intracellular MCP-1 under basal culture conditions, we found that PGE 2 induces a rapid and massive release of MCP-1 from MCs (Fig.  1A) . After only 30 min exposure to PGE 2 , MC culture supernatants contained greater than 100 pg/ml MCP-1. Levels of MCP-1 reached a plateau of ϳ700 pg/mL by 2 h (Fig. 1A) and were maintained at approximately the same levels over a 5-day incubation period (not shown). Semiquantitative PCR analysis showed that BMMCs constitutively express MCP-1 mRNA, which is consistent with a previous report [55] , and that PGE 2 minimally affects MCP-1 mRNA levels after 0.5, 1, 2, 3, 6, and 9 h incubation (Fig. 1B) . PGE 2 dose-dependently promoted MCP-1 release from BMMCs, and maximal effects were seen at PGE 2 concentrations of 1000 -5000 nM (Fig. 1C) . Similar MCP-1 release was observed in SPMCs stimulated with PGE 2 : After 1 h stimulation with PGE 2 at 1000 nM, MCP-1 levels in culture supernatant were 271.28 Ϯ 9.90 pg/mL/10 6 cells as opposed to only 18.01 Ϯ 0.68 pg/mL/10 6 cells in medium without PGE 2 . The viability of MC was not affected by shortterm (2 h) and long-term (5 days) exposure to 1000 nM PGE 2 , as determined by trypan blue exclusion (data not shown).
MC degranulation, induced by aggregation of FcεRI receptor I or by thrombin and a variety of chemical mediators, is complete within 40 min [56 -59] . We assessed whether degranulation is the mechanism underlying MCP-1 release from MCs in the presence of PGE 2 . Using histamine release as a marker for MC degranulation [48] , we measured levels of MCP-1 (Fig.  1C) and histamine (Fig. 1D ) in culture supernatants of MCs exposed to PGE 2 (1-5000 nM) for 1 h. We found that PGE 2 does not promote histamine release in BMMCs even at the highest concentration (5000 nM; Fig. 1D ), which reproducibly promotes MCP-1 release (Fig. 1C) . By contrast, the calcium ionophore A23187, a strong stimulator of MC degranulation, induced histamine and MCP-1 release. In addition, PMA, which has been reported not to induce MC degranulation [60, 61] , promoted MCP-1 but not histamine release from BMMCs (Fig. 1C) . We also confirmed that PGE 2 does not induce histamine release from MCs after longer incubation (Fig. 1A) .
In similar experiments, PGE 2 and PMA promoted MCP-1 release from SPMCs (medium only: 18.01Ϯ0.68 pg/mL/10 6 cells; PGE 2 5000 nM: 289.73Ϯ16.90 pg/mL/10 6 cells; PMA 100 nM: 298.36Ϯ9.92 pg/mL/10 6 cells at 1 h incubation) with minimal histamine release (medium only: 2.18Ϯ0.07%; PGE 2 5000 nM: 17.30Ϯ0.23%; PMA 100 nM: 2.47Ϯ0.04%), whereas the calcium ionofore A23187 (1000 nM) induced histamine (72.51Ϯ2.28%) and MCP-1 (336.33Ϯ6.58 pg/mL/ 10 6 cells) release. We also found that SPMC released a minimal amount of histamine after 24 h exposure to PGE 2 (medium only: 1.78Ϯ0.07%; PGE 2 1000 nM: 5.70Ϯ0.70%). These results provide evidence that PGE 2 can induce MCs to rapidly release MCP-1 without promoting their degranulation.
Analysis of CCR2 expression in MCs from mouse bone marrow and spleen
Previous studies revealed that MCP-1 is a potent inducer of degranulation from rat peritoneal MCs and murine pulmonary MCs but not from BMMCs [62, 63] . PGE 2 was reported not to induce degranulation from BMMCs by itself but to facilitate degranulation induced by ionomycin or IgE/antigen [35, 64] . As shown above (Fig. 1A) , we confirmed that PGE 2 does not induce BMMC or SPMC degranulation alone or in conjunction with MCP-1 present in MC culture supernatant after incubation with PGE 2 . To investigate the reason for the failure of MCP-1 to promote degranulation in BMMCs and SPMCs, we evaluated expression of CCR2, the specific MCP-1 receptor. RT-PCR analysis revealed low-level CCR2 expression in BMMCs and SPMCs compared with a positive control RNA from mouse kidney (Fig. 1E) , a result consistent with a previous report [65] . These results were confirmed with MCs from a different passage (data not shown). By flow cytometry, CCR2 was undetectable on BMMCs (Fig. 1F) and SPMCs (not shown). By contrast, surface CCR2 was detectable on WEHI-3 cells, which are known to express CCR2 only weakly [50] (Fig. 1F) .
Ultrastructural localization of MCP-1
Previous studies reported that BMMCs constitutively express MCP-1 mRNA at high levels [55, 65] . We found that murine , which were incubated with the addition of PMA (100 nM), the calcium ionophore A23187 (1000 nM), PGE 2 at varying concentrations (1-5000 nM), or control (0.1% ethanol) for 60 min at 37°C. MCP-1 and histamine content in culture supernatants were measured by specific ELISAs. Histamine was also measured in the cell pellet after boiling for 20 min. The percent histamine release was calculated as follows: histamine in the supernatant/(histamine in the supernatantϩhistamine in the pellet) ϫ 100 (%). The results shown reflect the means of triplicate determinations and were confirmed in an additional experiment. (E) RT-PCR analysis of CCR2 expression in BMMCs and SPMCs under basal culture conditions. RNA from mouse kidney served as a positive control. Results are representative of two independent experiments. (F) FACS analysis of CCR2 expression on BMMCs and WEHI-3 cells, which were cultured under basal conditions and were stained with a rat anti-mouse CCR2 mAb or isotype-matched control mAb, followed by an Alexa 488-labeled anti-rat IgG antibody. Results are representative of three independent experiments.
MCs contain ϳ800 pg MCP-1 protein/10 6 cells. The ability of PGE 2 to induce the secretion of MCP-1 without histamine release (degranulation) in BMMCs suggested the involvement of a secretory process other than degranulation. Therefore, we examined the ultrastructural localization of MCP-1 in BMMCs maintained under basal culture conditions. As shown in Figure 2A , BMMCs possess ultrastructural characteristics that are typical of MC, including a monolobed nucleus with partially condensed peripheral chromatin and numerous granules filled with electron-dense material. Immunochemical staining for MCP-1 revealed the presence of specific vesicle-like clusters of gold particles, which were not observed in control slides stained with an isotype-matched antibody (Fig. 2B, arrowhead) . In addition, MCP-1 was detected exclusively outside the MCspecific granules (Fig. 2B, arrow) . These results confirm the presence of pre-formed MCP-1 in BMMCs and provide evidence that MCP localizes outside the secretory granules in these cells.
Effects of DM and CsA on MC release of MCP-1
CsA and DM are potent immunosuppressant agents, which can variously affect MC function, including signaling, cytokine production, degranulation, and chemotaxis [51, 52, 66, 67] . We examined the effects of CsA and DM on PGE 2 -induced MC release of MCP-1. After 1 h incubation with CsA (1 g/mL), PGE 2 -activated BMMC released significantly less MCP-1 compared with BMMC not treated with CsA ( Fig. 2A) . As previous studies have demonstrated that CsA can reversibly inhibit exocytosis from cytotoxic T lymphocytes [53] , we tested whether CsA inhibition of MCP-1 release from MCs is also reversible. We found that cell-washing to remove CsA increased only minimally the amounts of MCP-1 measured in the culture supernatants (Fig. 3A) . DM (500 nM, 20 h exposure) also significantly reduced MCP-1 release in BMMC induced by PGE 2 (Fig. 3B) . Washing the MCs after 20 h exposure to DM did not reduce the effect of DM (Fig. 3B) . CsA (1 g/mL) and DM (500 nM) did not affect the viability of BMMC measured at the end of incubation. In additional experiments, we determined that CsA and DM exerted similar inhibition of MCP-1 release in SPMCs stimulated with PGE 2 (100.00Ϯ10.28% in medium only as opposed to 37.18Ϯ2.28 in 500 nM DM, PϽ0.01; 100.00Ϯ8.08% in medium only as opposed to 38.24Ϯ2.48% in 1 g/ml CsA, PϽ0.005; washing the cells after exposure to CsA or DM did not change the effects of these agents significantly).
Identification of PGE 2 receptor subtypes responsible for MCP-1 secretion PGE 2 receptors belong to four subtypes designated EP 1 , EP 2 , EP 3 , and EP 4 [25] . To identify the PGE 2 receptor(s) mediating Fig. 3 . Effects of CsA and DM on BMMC release of MCP-1. BMMCs (10 6 cells/mL) were pretreated with CsA (A) for 1 h or with DM (B) for 18 h; subsequently, PGE 2 (1000 nM) was added directly into the culture or after cell-washing to remove residual CsA or DM. MCP-1, present in the culture supernatant, was measured by a specific ELISA. Ethanol (0.1%) was used as a control for PGE 2 . The percent MCP-1 released was calculated as follows: (MCP-1 release in CsA or DM group/MCP-1 release in control group) ϫ 100 (%). Data shown reflect the means (ϮSD) of triplicate cultures and were confirmed in two repeat experiments. *, MCP-1 secretion from CsA-or DM-treated BMMCs is significantly different from that of control BMMCs (*, Ͻ0.05; **, Ͻ0.005).
the (Fig. 4A) . The EP 1 receptor agonist 17-phenyl--trinor-PGE 2 [68] and sulprostone, which binds with high-affinity to the EP 3 receptor and to a lesser extent, to the EP 1 receptor [35, 68] , induced the release of MCP-1 (Fig. 4B) . Sulprostone induced greater MCP-1 release than 17-phenyl--trinor-PGE 2 (PϽ0.05). The EP 3 /EP 4 receptor-selective agonist PGE 1 alcohol [68] also induced MCP-1 release, whereas the EP 2 receptor-selective agonist butaprost [36, 68] did not (Fig. 4B) . Taken together, these results suggest that the PGE 2 receptors EP 1 and EP 3 can mediate MCP-1 release from MCs, but involvement of the EP 4 receptor cannot be ruled out.
PGE 2 increases VEGF-A release from MCs
Previously, we have demonstrated that primary, murine MCs express the proangiogenic factors VEGF-A, VEGF-B, VEGF-C, and Ang-1 [8] . We now examined whether PGE 2 can regulate the expression of these genes in MCs. RNA was extracted from BMMCs cultured (10 6 cells/mL in complete culture medium) with or without PGE 2 (1000 nM) for 12 h. By qRT-PCR analysis, we found that PGE 2 treatment of BMMC results in a significantly (PϽ0.005) increased expression of VEGF-A but not of VEGF-B, VEGF-C, or Ang-1 (Fig. 5A) . Using a specific ELISA to measure VEGF-A in culture supernatants, we found that PGE 2 can increase by approximately twofold the levels of VEGF-A released by BMMCs (Fig. 5B) .
These increased levels of VEGF-A in BMMC culture supernatants could not be attributed to an increased MC number, as PGE 2 does not promote the growth of BMMC. Rather, at a higher concentration (5000 nM), PGE 2 inhibited the proliferation of BMMC (PϽ0.05; Fig. 5C ). This increase in VEGF-A secretion was sustained at least for 120 h. In parallel experiments, we found that PGE 2 can also enhance VEGF-A production in SPMCs (181.68Ϯ3.16 pg/mL/10 6 cells with 1000 nM PGE 2 as opposed to 102.85Ϯ4.85 pg/mL/10 6 cells in medium only; 120 h incubation). After 120 h incubation, PGE 1 alcohol, the EP 3 /EP 4 agonist, increased VEGF-A secretion in BMMCs to a similar degree as that induced by PGE 2 (224.14Ϯ12.07 pg/mL with 1000 nM PGE 2 ; 224.14Ϯ1.45 pg/mL with 1000 nM PGE 1 alcohol; 155.91Ϯ7.88 in medium alone).
DISCUSSION
MCs are often abundant in inflammatory infiltrates associated with a variety of pathological conditions, including asthma [69] , rheumatoid arthritis [70] , inflammatory bowel disease [71] , graft rejection [72] , coronary arteriosclerosis [73] , and a variety of cancers [74 -77] . Recently, there has been great interest in the contribution of MC to inflammation-associated angiogenesis, particularly in the context of malignant transformation and tumor progression [5, 7, 8, 75, 78, 79] . PGs, among the most characterized proinflammatory mediators implicated in cancer development [80, 81] , have been reported to variously modulate tumor angionenesis [82, 83] . Thus, PG receptor null mice displayed reduced tumor angiogenesis [82] , whereas mice that overexpress COX-2, an enzyme that promotes the conversion of AA into PGs, displayed increased tumor angiogenesis [83] . However, little is known about PGE 2 modulation of MC-associated angiogenesis.
Here, we report that PGE 2 induces the prompt and massive release of the proangiogenic chemokine MCP-1 from murine MCs. This activity of PGE 2 was not reported previously. Instead, it was noted previously that PGE 2 inhibits MCP-1 release from synovial fibroblasts stimulated with IL-1␤ [84] . Recently, IL-1 was reported to induce MC release of newly synthesized IL-6, which was first detected 3 h after IL-1 exposure and peaked at 18 h [85] . MCP-1 release from MCs is complete within 2 h from exposure to PGE 2 and is not associated with increased MCP-1 gene transcription, suggesting that MCP-1 is secreted from pre-stored deposits. It is important that PGE 2 -induced MCP-1 secretion was not accompanied by degranulation. This observation is in agreement with previous studies showing that PGE 2 alone does not induce MC degranulation [35, 61] . It is interesting that MCP-1 has been reported to induce degranulation from rat peritoneal MCs and murine pulmonary MCs but not from BMMCs [62, 63] . Here, we found that CCR2, the specific MCP-1 receptor, is undetectable on the surface of BMMCs and SPMCs, suggesting that insufficient levels of CCR2 are the likely cause for the failure of these cells to degranulate in response to MCP-1 induced by PGE 2 . Some studies have reported that PGE 2 may even reduce MC degranulation induced by FcεRI receptor I cross-linking with anti-IgE antibodies or by treatment with calcium ionophore A23187 [86 -88] , but other studies have suggested that PGE 2 can potentiate MC degranulation induced by ionomycin or by IgE/ antigen complexes [35, 64] . Such differences could relate to heterogeneities among MC subtypes [89] . We also found that PMA, which like PGE 2 , does not induce degranulation [35] , can promote MCP-1 release from MCs. Immunoelectron microscopy studies have provided evidence that IL-1-induced, newly synthesized IL-6 predominantly localizes in vesicle-like clusters, which are distinct from secretory granules, and is secreted from MCs independently of degranulation [85] . Similarly, in the current study, immunoelectron microscopic analysis revealed that MCP-1 does not localize to the secretory granules in BMMCs but rather at distinct intracytoplasmic sites. Taken together, previous studies and the results presented here provide evidence that MCs can store synthesized cytokines at specific sites distinct from secretory granules and possess mechanisms for rapid exocytosis of pre-formed cytokines other than degranulation.
PGE 2 exerts its activities on target cells through interaction with specific G protein-coupled receptors, of which there are four subtypes (EP 1 , EP 2 , EP 3 , and EP 4 ). EP 3 and EP 4 receptors are ubiquitously expressed in tissues, whereas EP 1 expression is somewhat more limited and is most abundant in the kidney [90] . By Northern analysis, BMMCs express EP 1 , EP 3 , and EP 4 but not EP 2 [61] . By RT-PCR analysis, low-level EP 2 expression is detected in BMMCs [61] . By using selective receptor agonists to identify the EP receptors that mediate PGE 2 -induced MCP-1 secretion in BMMCs, we demonstrate that the Several studies aimed at clarifying the proangiogenic properties of PGE 2 have focused on its ability to induce VEGF-A secretion in different cell types [82, [91] [92] [93] [94] [95] . Recently, it was noted that human MCs derived from the umbilical cord blood mononuclear cells constitutively produce VEGF-A and that PGE 2 is approximately threefold more effective than the IgEanti-IgE complex at stimulating VEGF-A release from IgEsensitized MCs without causing degranulation [36] . The authors concluded that the EP 2 subtype receptor is the main mediator of PGE 2 -induced VEGF-A secretion by human cord blood-derived MCs [36] . We could confirm that PGE 2 promotes VEGF-A production in murine MCs, but the levels of VEGF-A measured in the culture supernatant of PGE 2 -stimulated murine MCs are lower than those detected in the culture supernatants of PGE 2 -stimulated human cord blood-derived MCs. The lower level of VEGF-A produced by murine MCs as opposed to human cord blood-derived MCs could be attributed to differences in distribution of PGE 2 receptors. Human cord blood-derived MCs express EP 1 , EP 2 , EP 3 , and EP 4 subtype receptors [36] , and murine BMMCs express EP 1 , EP 3 , and EP 4 but lack expression or express EP 2 at low levels [35, 61] .
MCP-1 exerts its biological activities by binding and activating the G protein-coupled receptor CCR2 expressed on monocytes, endothelial cells, T lymphocytes, and natural killer cells. The release of MCP-1 by MCs induced by PGE 2 is expected to recruit all these cell populations to sites of inflammation, as MCs have been reported to be a major source of MCP-1 [16] . In particular, monocytes are a rich source of myriad angiogenic factors including VEGF-A, Ang-1, bFGF, transforming growth factor-␤1, platelet-derived growth factor, TNF-␣, hepatocyte growth factor, and insulin-like growth factor, suggesting that MCP-1 may exert some of its proangiogenic activities acting indirectly through the monocyte [23, 79, 96, 97] . It is interesting that recent studies about PGE 2 modulation of MCP-1 activities have described a more vigorous monocyte chemotactic response to MCP-1 in the presence of PGE 2 [98] , suggesting that PGE 2 may exert additional stimulatory activities on monocytes. Endothelial cells have been shown to express a functional CCR2 receptor and to be responsive to MCP-1 [21] . In addition to promoting endothelial cell chemotaxis, MCP-1 has been reported to directly stimulate endothelial cell sprouting [21] , a process that would be markedly enhanced by VEGF-A produced by MCs. Thus, MCP-1 and VEGF-A released by MCs during inflammation are likely to serve important, complementary, proangiogenic functions.
In summary, PGE 2 induces murine MCs to promptly release MCP-1 and to increase VEGF-A secretion. These observations provide evidence supporting a role for PGE 2 as a regulator of angiogenesis, in addition to inflammation and immunity. Understanding the diverse activities of PGE 2 is critical to the development of new therapies for targeting inflammation.
